Medicine and Dentistry
Radioembolization
100%
Cryoablation
84%
Hepatocellular Carcinoma
79%
Catheter Ablation
67%
Pulmonary Shunt
63%
Neoplasm
43%
Thoracic Duct
42%
Pulmonary Embolism
42%
Disease
40%
Adverse Event
37%
Systemic Therapy
32%
Cholangiocarcinoma
31%
Yttrium 90
30%
Surgical Risk
29%
Bleeding
28%
Interventional Radiology
26%
Technetium-99
26%
Scintigraphy
25%
Gallbladder Disease
25%
Single Photon Emission Computed Tomography-Computed Tomography
25%
Angiography
25%
Biopsy
25%
Embolization
21%
Radiofrequency Ablation
21%
Portal Hypertension
21%
Glyceryl Trinitrate
21%
Primary Tumor
21%
Desmoid Tumor
21%
Tilsotolimod
21%
Personalized Medicine
21%
Combined Therapy
21%
Interventional Radiologist
21%
Anticoagulation
21%
Hemodynamic
21%
Chronic Cholecystitis
21%
Metastatic Carcinoma
21%
Fluciclovine F 18
21%
Nephrology
21%
Stent-Graft
21%
Solid Malignant Neoplasm
21%
Toll Like Receptor 9
21%
Nonalcoholic Fatty Liver
21%
Antigen Presentation
21%
Fluorescent Dye
21%
In Silico
21%
Ex Vivo
21%
Bone Scintigraphy
21%
Positron Emission Tomography-Computed Tomography
21%
Fluorine-18
21%
Viscera
21%
Keyphrases
Hepatocellular Carcinoma
26%
Percutaneous Radiofrequency Ablation
21%
Liver
21%
Cortical Precursors
21%
Human Gallbladder
21%
Perfusion Angiography
21%
Thoracic Duct Stent
21%
Locoregional Therapy
21%
Transarterial Radioembolization
21%
Ablation Zone
21%
Nonalcoholic Steatohepatitis
21%
Cryoablation
21%
Retrospective Analysis
21%
Treatment Landscape
21%
Non-alcoholic Fatty Liver Disease (NAFLD)
21%
Fluciclovine PET
21%
Implementation Research
21%
FDA-approved Drugs
21%
Optical Biopsy
21%
Fluorescent Dye
21%
In Silico Design
21%
Hepatic Radioembolization
21%
Lung Shunt Fraction
21%
Hepatopulmonary Shunt
21%
18F-NaF PET-CT
21%
Treatment Strategy
15%
99mTc-MAA
15%
Background Liver
15%
Cranio-caudal
12%
Treatment Sequence
10%
Dissemination Research
10%
NR2F1
10%
State of Repair
10%
Accessible Chromatin Regions
10%
Reprogramming Genes
10%
In Situ
10%
Radioembolization Therapy
10%
Unresectable Hepatocellular Carcinoma
10%
Yttrium-90 Radioembolization
10%
Overall Survival
9%
Progression-free Survival
9%
Abscopal Effect
7%
Moderate Sedation
7%
Local Recurrence-free Survival
7%
Cryoprobe
7%
Hepatobiliary Iminodiacetic Acid
7%
Poor Surgical Candidates
7%
Patient Sequencing
7%
Immune Analysis
7%
Four-step Approach
7%